LPP
MCID: PST062
MIFTS: 48

Pustulosis Palmaris Et Plantaris (LPP)

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Pustulosis Palmaris Et Plantaris

MalaCards integrated aliases for Pustulosis Palmaris Et Plantaris:

Name: Pustulosis Palmaris Et Plantaris 53 59 55 33
Localized Pustular Psoriasis 53 59 72
Palmoplantar Pustulosis 53 59
Ppp 53 59
Lpp 53 59
Generalized Pustular Psoriasis 72
Pustulosis of Palms and Soles 72

Characteristics:

Orphanet epidemiological data:

59
pustulosis palmaris et plantaris
Inheritance: Autosomal dominant,Autosomal recessive;

Classifications:

Orphanet: 59  
Rare skin diseases


External Ids:

ICD10 33 L40.3
ICD10 via Orphanet 34 L40.3
UMLS via Orphanet 73 C0030246
Orphanet 59 ORPHA163927
UMLS 72 C0030246 C0263365 C0343055

Summaries for Pustulosis Palmaris Et Plantaris

NIH Rare Diseases : 53 Pustulosis palmaris et plantaris (PPP) is a rare and chronic inflammatory condition that primarily affects the palms of the hands and soles of the feet. Signs and symptoms of the condition generally develop during adulthood and include crops of pustules on one or both hands and/or feet that erupt repeatedly over time. Affected individuals may also experience itching (pruritus), pain, or a burning sensation. The classification of PPP is controversial. Some have proposed that PPP is a variant of psoriasis, while others believe it to be a separate disease. Though the area of involvement is often limited, PPP can have a significant effect on quality of life and can interfere with walking or other daily activities. PPP often has a chronic and relapsing course and may be resistant to treatment. Treatment options may include topical steroids, emollients, certain medications called retinoids, and treatment with light (phototherapy).

MalaCards based summary : Pustulosis Palmaris Et Plantaris, also known as localized pustular psoriasis, is related to pustulosis of palm and sole and iga glomerulonephritis. An important gene associated with Pustulosis Palmaris Et Plantaris is AP1S3 (Adaptor Related Protein Complex 1 Subunit Sigma 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ixekizumab and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and tonsil, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 75 Pustulosis palmaris et plantaris is a chronic recurrent pustular dermatosis (that is, a pustulosis or... more...

Related Diseases for Pustulosis Palmaris Et Plantaris

Diseases related to Pustulosis Palmaris Et Plantaris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 276)
# Related Disease Score Top Affiliating Genes
1 pustulosis of palm and sole 31.4 TNF IL36RN AP1S3
2 iga glomerulonephritis 31.0 TGFB1 CD79A CD40LG
3 vasculitis 30.6 TNF SELE ELANE CD40LG
4 lichen planus 30.2 TNF ITGAL CXCR3
5 proteasome-associated autoinflammatory syndrome 1 30.1 TNF SELE IL5 ELANE
6 psoriasis 14, pustular 30.0 IL36RN AP1S3
7 pyoderma 29.9 TNF ITGB2 IL36RN
8 contact dermatitis 29.9 TNF SELE IL5 CXCR3
9 pustular psoriasis 29.8 TNF IL36RN ELANE AP1S3
10 mycosis fungoides 29.6 ITGB2 ITGAL IL5 CXCR3 CCR4
11 skin disease 29.0 TNF SELE ITGAL IL5 IL36RN CD79A
12 rheumatoid arthritis 28.1 TNF TGFB1 SELE ITGB2 ITGAL CD40LG
13 lichen planopilaris 12.2
14 periodontitis, aggressive, 1 12.1
15 lichen planus pigmentosus 11.8
16 lipomatosis, multiple 11.7
17 psoriasis 1 11.7
18 vacterl association 11.7
19 esophageal atresia 11.7
20 pneumonic plague 11.6
21 leukemia, acute myeloid 11.6
22 seborrheic dermatitis 11.6
23 lichen planus pemphigoides 11.5
24 bartsocas-papas syndrome 11.5
25 transaldolase deficiency 11.4
26 congenital anomalies of kidney and urinary tract 2 11.2
27 androgenic alopecia 11.2
28 paraphilia disorder 11.2
29 chondroid lipoma 11.2
30 pedophilia 11.2
31 enamel erosion 11.2
32 hair disease 11.2
33 acute t cell leukemia 11.2
34 infiltrating lipoma 11.2
35 lichen disease 11.2
36 prostate carcinoma in situ 11.2
37 cebpa-associated familial acute myeloid leukemia 11.2
38 pseudopelade of brocq 11.2
39 psoriasis 10.9
40 tonsillitis 10.9
41 bone inflammation disease 10.8
42 periodontitis 10.7
43 pleomorphic lipoma 10.7
44 c1q nephropathy 10.7 CD79A CD40LG
45 immunoglobulin g deficiency 10.7 CD79A CD40LG
46 cryofibrinogenemia 10.6 CD79A CD40LG
47 pulmonary alveolar microlithiasis 10.6
48 sleep apnea 10.6
49 metal allergy 10.6
50 osteomyelitis 10.6

Graphical network of the top 20 diseases related to Pustulosis Palmaris Et Plantaris:



Diseases related to Pustulosis Palmaris Et Plantaris

Symptoms & Phenotypes for Pustulosis Palmaris Et Plantaris

GenomeRNAi Phenotypes related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCL20 CCR6 CD79A IL5 ITGAL SELE

MGI Mouse Phenotypes related to Pustulosis Palmaris Et Plantaris:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CCR4 CCR6 CD40LG CD79A CXCR3 ELANE
2 homeostasis/metabolism MP:0005376 10.24 CCR6 CD40LG CD79A CXCR3 ELANE IL36RN
3 immune system MP:0005387 10.22 CCR4 CCR6 CD40LG CD79A CXCR3 ELANE
4 cellular MP:0005384 10.17 CD40LG CD79A CXCR3 ITGAL ITGB1 ITGB2
5 cardiovascular system MP:0005385 10.11 CD40LG CXCR3 IL36RN ITGB1 ITGB2 SELE
6 integument MP:0010771 9.91 CD40LG IL36RN ITGB1 ITGB2 SELE SELPLG
7 neoplasm MP:0002006 9.76 CD79A CXCR3 ELANE IL5 ITGAL ITGB1
8 normal MP:0002873 9.61 CCR6 CD79A CXCR3 ELANE IL36RN ITGB1
9 respiratory system MP:0005388 9.17 CCR4 CXCR3 IL5 ITGB1 SELE TGFB1

Drugs & Therapeutics for Pustulosis Palmaris Et Plantaris

Drugs for Pustulosis Palmaris Et Plantaris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
2
Adalimumab Approved Phase 3 331731-18-1 16219006
3
tannic acid Approved Phase 3 1401-55-4
4
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
5
Etanercept Approved, Investigational Phase 3 185243-69-0
6
Certolizumab pegol Approved Phase 2, Phase 3 428863-50-7
7
Infliximab Approved Phase 3 170277-31-3
8 Brodalumab Approved, Investigational Phase 3 1174395-19-7
9 Antibodies Phase 3
10 Immunoglobulins Phase 3
11 Antibodies, Monoclonal Phase 3
12 Immunologic Factors Phase 3
13 Antirheumatic Agents Phase 3
14 Gastrointestinal Agents Phase 3
15 Pharmaceutical Solutions Phase 3
16 Dermatologic Agents Phase 3
17
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
18 Antineoplastic Agents, Immunological Phase 2
19 Vaccines Phase 2
20 Interleukin 1 Receptor Antagonist Protein Phase 2
21 Anti-Inflammatory Agents Phase 2
22 Analgesics Phase 2
23 Analgesics, Non-Narcotic Phase 2
24 Peripheral Nervous System Agents Phase 2
25 Anti-Inflammatory Agents, Non-Steroidal Phase 2
26 Immunosuppressive Agents Phase 2
27 Angiogenesis Inhibitors Phase 2
28 Anti-Infective Agents Phase 2
29 Angiogenesis Modulating Agents Phase 2
30 Anti-Bacterial Agents Phase 2
31
Sargramostim Approved, Investigational Phase 1 83869-56-1, 123774-72-1
32
Lenograstim Approved, Investigational Phase 1 135968-09-1
33 Adjuvants, Immunologic Phase 1

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Recruiting NCT03942042 Phase 4 Ixekizumab
2 A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability in Japanese Subjects With Generalized Pustular Psoriasis Completed NCT01952015 Phase 3
3 A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis Completed NCT02533375 Phase 3 Adalimumab
4 A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis Completed NCT02641730 Phase 3 Guselkumab;Placebo
5 A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Completed NCT02343744 Phase 3 Guselkumab
6 Phase 3 Study With a Placebo-Controlled, Double-blind, on the Safety and Efficacy of Etanercept in Palmo-Plantar Pustulosis Completed NCT00353119 Phase 3 Placebo comparator;Etanercept
7 Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis Completed NCT03051217 Phase 2, Phase 3 Certolizumab Pegol
8 A Double-Blind Study on the Safety and Efficacy of Infliximab in Palmoplantar Psoriasis Completed NCT00629772 Phase 3 Placebo;Infliximab
9 A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis - Amended With an Optional Extension Treatment Period of up to a Total of 148 Weeks Completed NCT02008890 Phase 3
10 An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of BI 655130 Treatment in Patients With Generalized Pustular Psoriasis (GPP) Recruiting NCT03886246 Phase 3 Spesolimab;Spesolimab
11 A Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Active, not recruiting NCT03022045 Phase 3 risankizumab
12 A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar Pustulosis Not yet recruiting NCT04061252 Phase 3 KHK4827;Placebo
13 Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP) Completed NCT03135548 Phase 2 BI 655130 (low dose);Placebo;BI 655130 (high dose)
14 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody, Following Subcutaneous Administration in Subjects With Palmoplantar Pustulosis Completed NCT01845987 Phase 2 Placebo;CNTO 1959
15 A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis Recruiting NCT03619902 Phase 2 ANB019
16 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis Recruiting NCT03988335 Phase 2 RIST4721;Placebo
17 Effisayil™ 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of BI 655130 in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe Intensity. Recruiting NCT03782792 Phase 2 Spesolimab;Placebo
18 A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis Recruiting NCT03633396 Phase 2 Placebo
19 A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms Recruiting NCT01794117 Phase 2 Anakinra
20 Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) Recruiting NCT04015518 Phase 2 BI 655130;Placebo
21 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis Not yet recruiting NCT04057937 Phase 2 Apremilast;Placebo
22 Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Pustulosis Terminated NCT01197989 Phase 2
23 Multi-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of BI 655130 in Patients With Active Generalized Pustular Psoriasis. Completed NCT02978690 Phase 1 BI655130
24 A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Not yet recruiting NCT03972280 Phase 1
25 The Immune Signature of Palmoplantar Pustulosis Completed NCT01780857

Search NIH Clinical Center for Pustulosis Palmaris Et Plantaris

Genetic Tests for Pustulosis Palmaris Et Plantaris

Anatomical Context for Pustulosis Palmaris Et Plantaris

MalaCards organs/tissues related to Pustulosis Palmaris Et Plantaris:

41
Neutrophil, Skin, Tonsil, T Cells, Testes, Bone

Publications for Pustulosis Palmaris Et Plantaris

Articles related to Pustulosis Palmaris Et Plantaris:

(show top 50) (show all 191)
# Title Authors PMID Year
1
What do we know about palmoplantar pustulosis? 6
27521275 2017
2
Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects. 6
27113059 2016
3
Levels of proelafin peptides in the sera of the patients with generalized pustular psoriasis and pustulosis palmoplantaris. 9 38
10877128 2000
4
Soluble E-selectin as a marker of disease activity in pustulosis palmaris et plantaris. 9 38
10598762 1999
5
Medullasin levels in neutrophils of patients with pustulosis palmaris et plantaris. 9 38
8315109 1993
6
Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis. 38
29896852 2019
7
Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis: A retrospective subjective and objective quantitative analysis of 138 patients. 38
29732605 2018
8
Could Psoriatic Arthritis Be Easily Diagnosed from Current Suspicious Physical Findings in the Dermatology Clinic? 38
28223746 2017
9
Identification of nail features associated with psoriasis severity. 38
27599783 2017
10
Cefcapene Pivoxil Hydrochloride Is a Potentially New Treatment for Palmoplantar Pustulosis with Pustulotic Arthro-Osteitis. 38
26440444 2015
11
Pustulosis palmaris et plantaris successfully treated with leukotriene antagonist. 38
25672791 2014
12
Caveolin-1 expression in different types of psoriatic lesions: analysis of 66 cases. 38
24891649 2014
13
Presence of keratin-specific antibody-forming cells in palatine tonsils of patients with pustulosis palmaris et plantaris (PPP) and its correlation with prognosis after tonsillectomy. 38
24138121 2014
14
Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. 38
25330301 2014
15
Pustulosis palmaris et plantaris. 38
23709543 2013
16
Cutaneous small vessel vasculitis accompanied by pustulosis palmaris et plantaris. 38
22548039 2012
17
Improvement of pustulosis palmaris et plantaris by periodontal infection control in a patient with chronic periodontitis. 38
22582507 2012
18
Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. 38
21951304 2011
19
Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. 38
21732985 2011
20
Increased peripheral Th17 in patients with pustulosis palmaris et plantaris. 38
21229362 2011
21
Tonsil-related skin diseases and possible involvement of T cell co-stimulation in chronic focal infection. 38
21865697 2011
22
Up-regulation of ß1 integrin on tonsillar T cells and its induction by in vitro stimulation with α-streptococci in patients with pustulosis Palmaris et Plantaris. 38
20714794 2010
23
Unusual case of pemphigus vulgaris mimicking localized pustular psoriasis of the hands and feet. 38
21049731 2010
24
Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. 38
20393482 2010
25
Analysis of psoriatic patients registered in Asahikawa Medical College Hospital from 1983 to 2007. 38
19958446 2009
26
Pathogenic role of tonsillar lymphocytes in associated with HSP60/65 in Pustulosis palmaris et plantaris. 38
19268507 2009
27
Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris. 38
19659772 2009
28
Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study. 38
19222520 2009
29
Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? 38
18850415 2009
30
Assessment of allergic hypersensitivity to dental materials. 38
19458446 2009
31
Possible involvement of T cell co-stimulation in pustulosis palmaris et plantaris via the induction of inducible co-stimulator in chronic focal infections. 38
18308514 2008
32
[What's new in medicine in 2007?]. 38
18675138 2007
33
Pustulosis palmaris et plantaris with prominent hyperkeratosis of the soles. 38
17169098 2006
34
Regression of pustulosis palmaris et plantaris by periodontal treatment in a subject with severe periodontitis. 38
17184243 2006
35
[Maximilian Koenigsbeck and localized pustular psoriasis]. 38
16799814 2006
36
[A case report of a metal allergy patient whose prosthesis was identified allergenic by non-destructive metal element analysis and a dermatological patch test]. 38
16790970 2006
37
Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). 38
15925831 2005
38
Increase of activated T-cells and up-regulation of Smad7 without elevation of TGF-beta expression in tonsils from patients with pustulosis palmaris et plantaris. 38
15885643 2005
39
Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. 38
16205070 2005
40
Effect of tonsillectomy in patients with pustulosis palmaris et plantaris. 38
15513559 2004
41
Implication of responses to bacterial heat shock proteins, chronic microbial infections, and dental metal allergy in patients with pustulosis palmaris et plantaris. 38
14694830 2003
42
The role of mercury in pustulosis palmaris et plantaris. 38
12762071 2003
43
A case of pustulosis palmaris et plantaris that began as generalized pustular eruption. 38
12692382 2003
44
A survey of psoriasis patients in Japan from 1982 to 2001. 38
12615365 2003
45
New aspects of metal allergy. 38
12588671 2002
46
Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of hallopeau. 38
12234156 2002
47
[Oral antibiotics with antiinflammatory/ immunomodulatory effects in the treatment of various dermatoses]. 38
12219268 2002
48
Polymorphism of the vitamin D(3) receptor in patients with psoriasis. 38
12111344 2002
49
Pustular skin disorders: diagnosis and treatment. 38
12113648 2002
50
Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. 38
11296958 2001

Variations for Pustulosis Palmaris Et Plantaris

Expression for Pustulosis Palmaris Et Plantaris

Search GEO for disease gene expression data for Pustulosis Palmaris Et Plantaris.

Pathways for Pustulosis Palmaris Et Plantaris

Pathways related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TNF TGFB1 ITGB2 ITGB1 ITGAL IL5
2
Show member pathways
13.73 TNF TGFB1 ITGB2 ITGB1 ITGAL IL5
3
Show member pathways
13.63 TNF TGFB1 IL5 IL36RN CXCR3 CD40LG
4
Show member pathways
13.51 TNF TGFB1 SMAD7 ITGB2 ITGB1 ITGAL
5
Show member pathways
13.33 TGFB1 ITGB2 ITGB1 ITGAL CXCR3 CCR6
6
Show member pathways
13.32 TNF TGFB1 ITGB2 ITGB1 IL5 CD40LG
7
Show member pathways
13.28 TGFB1 SELPLG SELE ITGB2 ITGB1 ITGAL
8
Show member pathways
13.18 TNF TGFB1 IL5 CXCR3 CD40LG CCR6
9
Show member pathways
12.89 TNF TGFB1 ITGB2 ITGB1 ITGAL
10
Show member pathways
12.88 TNF ITGB2 ITGB1 ITGAL CD79A CD40LG
11
Show member pathways
12.84 TNF TGFB1 ITGB2 ITGB1 ITGAL IL5
12
Show member pathways
12.83 TNF TGFB1 ITGB2 ITGAL IL5 CD40LG
13
Show member pathways
12.71 TGFB1 ITGB2 ITGB1 ITGAL ELANE
14 12.53 TNF ITGB2 CD79A CD40LG
15
Show member pathways
12.53 TNF TGFB1 IL5 CD40LG
16 12.32 TNF TGFB1 ITGB2 ITGAL
17
Show member pathways
12.2 CXCR3 CCR6 CCR4 CCL20
18
Show member pathways
12.15 TNF TGFB1 ITGB2 ITGB1 CD40LG
19
Show member pathways
12.08 ITGB2 ITGB1 ITGAL CXCR3 CCR6 CCR4
20
Show member pathways
12.05 TGFB1 SELPLG SELE ITGB2 ITGB1 ITGAL
21 12.03 ITGB2 ITGB1 ITGAL CD40LG
22 11.94 TNF ITGAL IL5 CD79A
23 11.93 TNF SELE CCL20
24 11.89 TNF TGFB1 ITGB2 ITGB1
25 11.88 TNF TGFB1 ITGB2
26 11.87 TNF TGFB1 SELE
27 11.84 TNF TGFB1 SMAD7
28 11.8 ITGB2 ITGB1 ITGAL
29 11.8 SELPLG ITGB2 ITGAL
30 11.8 SELPLG SELE ITGB2 ITGB1 ITGAL CD40LG
31 11.74 TNF ITGB2 ITGB1
32
Show member pathways
11.73 TNF IL5 CD40LG
33 11.73 TNF TGFB1 ITGB2 ITGAL CCL20
34 11.7 TGFB1 ITGB2 ITGB1 ITGAL
35 11.7 TNF TGFB1 CCL20
36 11.7 TNF IL5 CXCR3 CCR6
37
Show member pathways
11.64 TNF SELE CD40LG
38 11.59 TNF TGFB1 SMAD7
39 11.56 TNF TGFB1 SMAD7 IL5
40 11.46 TGFB1 ITGB2 ITGAL
41
Show member pathways
11.44 ITGB2 ITGB1 ITGAL
42 11.44 ITGB2 ITGB1 ITGAL
43 11.39 TNF SELPLG ITGB2 ELANE
44 11.37 TGFB1 ITGB2 ITGB1 ITGAL
45 11.37 SELE ITGB1 ELANE
46 11.29 ITGB2 ITGAL CXCR3
47 11.2 TNF TGFB1 IL5
48 11.17 TNF IL5 CD40LG CCL20
49 10.85 TNF TGFB1
50 10.79 TNF TGFB1 SELE ITGB2 ITGAL CD40LG

GO Terms for Pustulosis Palmaris Et Plantaris

Cellular components related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.98 TNF SELPLG SELE CXCR3 CD40LG CCR6
2 cell surface GO:0009986 9.61 TNF TGFB1 ITGB2 ITGB1 ITGAL ELANE
3 membrane raft GO:0045121 9.55 TNF SELE ITGB2 ITGB1 CD79A
4 integrin complex GO:0008305 9.5 ITGB2 ITGB1 ITGAL
5 integrin alphaL-beta2 complex GO:0034687 9.26 ITGB2 ITGAL
6 external side of plasma membrane GO:0009897 9.23 TNF ITGB2 ITGB1 CXCR3 CD79A CD40LG
7 intracellular GO:0005622 9.16 SMAD7
8 plasma membrane GO:0005886 10.18 TNF TGFB1 SMAD7 SELPLG SELE ITGB2
9 extracellular space GO:0005615 10.01 TNF TGFB1 SELE IL5 IL36RN ELANE

Biological processes related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.9 ITGB2 ITGB1 ITGAL CD40LG
2 extracellular matrix organization GO:0030198 9.89 TNF ITGB2 ITGB1 ITGAL
3 chemotaxis GO:0006935 9.87 CXCR3 CCR6 CCR4 CCL20
4 cytokine-mediated signaling pathway GO:0019221 9.87 TNF TGFB1 ITGB2 ITGB1 IL5 IL36RN
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF TGFB1 ITGB2 CD40LG
6 transforming growth factor beta receptor signaling pathway GO:0007179 9.83 TGFB1 SMAD7 ITGB1
7 integrin-mediated signaling pathway GO:0007229 9.83 ITGB2 ITGB1 ITGAL
8 cell-matrix adhesion GO:0007160 9.83 ITGB2 ITGB1 ITGAL
9 neutrophil chemotaxis GO:0030593 9.81 ITGB2 IL36RN CCL20
10 B cell differentiation GO:0030183 9.8 ITGB1 CD79A CD40LG
11 cell chemotaxis GO:0060326 9.8 CXCR3 CCR6 CCR4 CCL20
12 calcium-mediated signaling GO:0019722 9.78 SELE CXCR3 CCR6 CCR4
13 positive regulation of MAP kinase activity GO:0043406 9.76 TNF TGFB1 ELANE
14 chemokine-mediated signaling pathway GO:0070098 9.76 CXCR3 CCR6 CCR4 CCL20
15 phagocytosis GO:0006909 9.73 ITGB2 ITGB1 ITGAL ELANE
16 positive regulation of superoxide anion generation GO:0032930 9.67 TGFB1 ITGB2
17 leukocyte tethering or rolling GO:0050901 9.67 TNF SELPLG SELE ITGB1
18 negative regulation of growth of symbiont in host GO:0044130 9.66 TNF ELANE
19 pathway-restricted SMAD protein phosphorylation GO:0060389 9.65 TGFB1 SMAD7
20 positive regulation of podosome assembly GO:0071803 9.64 TNF IL5
21 negative regulation of interleukin-17 production GO:0032700 9.64 TGFB1 IL36RN
22 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.63 TNF ELANE
23 germ cell migration GO:0008354 9.62 TGFB1 ITGB1
24 T cell migration GO:0072678 9.61 CCR6 CCL20
25 response to laminar fluid shear stress GO:0034616 9.61 TGFB1 SMAD7
26 regulation of immunoglobulin secretion GO:0051023 9.58 TNF CD40LG
27 cellular extravasation GO:0045123 9.56 TNF ITGB2
28 leukocyte migration involved in inflammatory response GO:0002523 9.56 SELE ITGB2 ELANE CCR6
29 leukocyte migration GO:0050900 9.56 TNF TGFB1 SELPLG SELE ITGB2 ITGB1
30 leukocyte cell-cell adhesion GO:0007159 9.55 SELE ITGB2 ITGB1 ITGAL CD40LG
31 positive regulation of mononuclear cell migration GO:0071677 9.52 TNF TGFB1
32 thymocyte migration GO:0072679 9.51 CCR6 CCL20
33 inflammatory response GO:0006954 9.36 TNF TGFB1 SELE ITGB2 ITGAL IL5
34 cell adhesion GO:0007155 10.01 SELPLG SELE ITGB2 ITGB1 ITGAL CXCR3
35 immune response GO:0006955 10.01 TNF IL5 IL36RN CXCR3 CD40LG CCR6

Molecular functions related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.65 TNF ITGB1 ELANE
2 cell adhesion molecule binding GO:0050839 9.61 ITGB2 ITGB1 ITGAL
3 chemokine binding GO:0019956 9.54 CXCR3 CCR6 CCR4
4 C-C chemokine binding GO:0019957 9.5 CXCR3 CCR6 CCR4
5 type I transforming growth factor beta receptor binding GO:0034713 9.46 TGFB1 SMAD7
6 ICAM-3 receptor activity GO:0030369 9.4 ITGB2 ITGAL
7 C-C chemokine receptor activity GO:0016493 9.33 CXCR3 CCR6 CCR4
8 chemokine receptor activity GO:0004950 9.13 CXCR3 CCR6 CCR4
9 cytokine activity GO:0005125 9.1 TNF TGFB1 IL5 IL36RN CD40LG CCL20
10 protein binding GO:0005515 10.19 TNF TGFB1 SMAD7 SELPLG SELE ITGB2

Sources for Pustulosis Palmaris Et Plantaris

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....